To increase the efficiency of medical treatment for 5 complex diseases, including cardiovascular disease stroke breast cancer uterine fibroids and kidney or gallbladder stones; and (iv) SSO’s upward lump sum adjustment), gross margin improved 2.6% to 30.2% (although the company cut revenue by Bt16mn for the margin). between actual and accrued revenue for COVID-19 treatment for SSO). Gross margin will increase to 30.5% BCH recorded a foreign exchange loss of 63 million baht, which lowered net profit to 284 million baht.
2H better profit
due to (i) more seasonal epidemics, (ii) realized full quarterly revenue in 3Q from SSO hike per capita. and income from risk burden in 3Q/4Q and SSO renewal of the pilot project for operative treatment of 5 disease groups until the end of December 2023 and (iii) income from health checks for employees in the estate in Nonthaburi employee mobile health check Of the Federation of Thai Industries 0.1-0.2 million people and the number of patients is increasing from Saudi Arabia, Libya (IVF) and China (IVF).
Implication/ Recommendation
BCH recorded core earnings of Bt617m in 1H23 or 40% of FY23F earnings. We expect earnings to strengthen in 2H23. ) and foreign exchange risk will be eliminated (loss of 193 million baht FY22) after repayment of the Thai baht loan (480 million baht) of KH Vientiane by Sep.
2023-08-16 08:09:00
#Individual #stock #analysis #Krungsri #Securities #BCH #2Q23 #earnings #close #estimates #companies
